U.S. Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
February 6, 2013
| Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act |
Dear Sirs,
Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission on February 6, 2013.
Sincerely,
| /s/ Lars Rebien Sørensen |
/s/
Jesper Brandgaard
|
|
|
|
|
|
| Lars Rebien Sørensen |
Jesper
Brandgaard
|
|
| President and Chief Executive Officer |
Executive
Vice President and Chief Financial Officer
|
| Novo Nordisk A/S |
Novo
Allé
DK-2880
Bagsværd
Denmark |
Telephone:
+45
4444 8888
Telefax +45 444 6626 |
Internet: |